Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera. That represents a premium of more than 42% to Metsera’s closing price last Friday.